Publication Name	World Journal of Gastroenterology
Manuscript ID	34057
Country	Canada

Received	2017-03-24 08:46
Peer-Review Started	2017-03-29 16:10
To Make the First Decision	2017-04-26 08:53
Return for Revision	2017-05-03 10:27
Revised	2017-05-16 02:32
Second Decision	2017-06-16 13:04
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2017-06-19 09:42
Articles in Press	2017-06-19 09:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-07-10 07:24
Publish the Manuscript Online	2017-07-20 10:12

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Systematic Reviews
Article Title	Management of inflammatory bowel disease with Clostridium difficile infection
Manuscript Source	Invited Manuscript
All Author List	Julie D'Aoust, Robert Battat and Talat Bessissow
Funding Agency and Grant Number
Corresponding Author	Talat Bessissow, MD, FRCPC, Division of Gastroenterology, McGill University Health Center, 1650 Avenue Cedar C7-200, Montreal QC H3G 1A4, Canada. talat.bessissow@mcgill.ca
Key Words	Biologic therapy; Clostridium difficile; Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Corticosteroids
Core Tip	Clostridium difficile infection (CDI), common and increasing in inflammatory bowel disease (IBD), is associated with worse outcomes in IBD. Vancomycin-containing regimens are effective first-line therapies for CDI in IBD. Ambiguity exists on the treatment of IBD flare in patients with CDI; however, case reports suggest corticosteroid initiation after appropriate antibiotic therapy may be effective.
Publish Date	2017-07-20 10:12
Citation	D’Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol 2017; 23(27): 4986-5003
URL	http://www.wjgnet.com/1007-9327/full/v23/i27/4986.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i27.4986

Full Article (PDF)	WJG-23-4986.pdf
Full Article (Word)	WJG-23-4986.doc
Manuscript File	34057-Review.docx
Answering Reviewers	34057-Answering reviewers.pdf
Audio Core Tip	34057-Audio core tip.mp3
Biostatistics Review Certificate	34057-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	34057-Conflict-of-interest statement.pdf
Copyright License Agreement	34057-Copyright assignment.pdf
Supplementary Material	34057_10 34057 Scientific research process.docx
Peer-review Report	34057-Peer-review(s).pdf
Scientific Misconduct Check	34057-Scientific misconduct check.pdf
Scientific Editor Work List	34057-Scientific editor work list.pdf